| Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 6180 | 2015 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 3001 | 2015 |
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ... Journal of clinical oncology 25 (13), 1658-1664, 2007 | 2420 | 2007 |
| Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 1942 | 2018 |
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study JD Wolchok, B Neyns, G Linette, S Negrier, J Lutzky, L Thomas, ... The lancet oncology 11 (2), 155-164, 2010 | 1422 | 2010 |
| Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet 390 (10105), 1853-1862, 2017 | 1299 | 2017 |
| Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019 | 1048 | 2019 |
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma TT Batchelor, P Mulholland, B Neyns, LB Nabors, M Campone, A Wick, ... Journal of Clinical Oncology 31 (26), 3212-3218, 2013 | 596 | 2013 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of Clinical Oncology 35 (2), 226-235, 2017 | 573 | 2017 |
| Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label … J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ... Journal of clinical oncology 36 (4), 383-390, 2018 | 523 | 2018 |
| Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed … R Stupp, ME Hegi, B Neyns, R Goldbrunner, U Schlegel, PMJ Clement, ... Journal of clinical oncology 28 (16), 2712-2718, 2010 | 518 | 2010 |
| First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study HJ Lenz, E Van Cutsem, M Luisa Limon, KYM Wong, A Hendlisz, ... Journal of clinical oncology 40 (2), 161-170, 2022 | 411 | 2022 |
| Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization AR Pombo Antunes, I Scheyltjens, F Lodi, J Messiaen, A Antoranz, ... Nature neuroscience 24 (4), 595-610, 2021 | 349 | 2021 |
| Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ... The lancet oncology 15 (4), 436-444, 2014 | 319 | 2014 |
| Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma S Wilgenhof, J Corthals, C Heirman, N van Baren, S Lucas, P Kvistborg, ... Journal of Clinical Oncology 34 (12), 1330-1338, 2016 | 305 | 2016 |
| Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, JF Baurain, ... Annals of Oncology 20 (9), 1596-1603, 2009 | 286 | 2009 |
| Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients A Bonehill, AMT Van Nuffel, J Corthals, S Tuyaerts, C Heirman, ... Clinical Cancer Research 15 (10), 3366-3375, 2009 | 272 | 2009 |
| Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab J de Filette, Y Jansen, M Schreuer, H Everaert, B Velkeniers, B Neyns, ... The Journal of Clinical Endocrinology & Metabolism 101 (11), 4431-4439, 2016 | 232 | 2016 |
| Current approaches in dendritic cell generation and future implications for cancer immunotherapy S Tuyaerts, JL Aerts, J Corthals, B Neyns, C Heirman, K Breckpot, ... Cancer Immunology, Immunotherapy 56, 1513-1537, 2007 | 229 | 2007 |
| Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA A Bonehill, S Tuyaerts, AMT Van Nuffel, C Heirman, TJ Bos, K Fostier, ... Molecular Therapy 16 (6), 1170-1180, 2008 | 217 | 2008 |
